Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) Share data in Millions, except Per Share data, unless otherwise specified	3 Months Ended		12 Months Ended										3 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended			3 Months Ended	12 Months Ended					3 Months Ended		12 Months Ended			3 Months Ended	12 Months Ended
	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2014 Revenue [Member] Customer Concentration Risk [Member] Medtronic [Member]	Sep. 30, 2013 Revenue [Member] Customer Concentration Risk [Member] Medtronic [Member]	Sep. 30, 2012 Revenue [Member] Customer Concentration Risk [Member] Medtronic [Member]	Sep. 30, 2014 Maximum [Member] USD ($)	Sep. 30, 2014 Maximum [Member] Revenue [Member] Customer Concentration Risk [Member]	Sep. 30, 2014 Maximum [Member] Revenue [Member] Product Concentration Risk [Member] Medtronic [Member]	Sep. 30, 2014 CeloNova BioSciences, Inc. [Member] Maximum [Member]	Sep. 30, 2014 ThermopeutiX, Inc. [Member] USD ($)	Sep. 30, 2014 ThermopeutiX, Inc. [Member] USD ($)	Sep. 30, 2014 ThermopeutiX, Inc. [Member] Maximum [Member]	Mar. 31, 2013 ViaCyte, Inc. [Member] USD ($)	Sep. 30, 2014 ViaCyte, Inc. [Member] USD ($)	Sep. 30, 2006 ViaCyte, Inc. [Member] USD ($)	Sep. 30, 2014 ViaCyte, Inc. [Member] Maximum [Member]	Dec. 31, 2012 Vessix Vascular, Inc. [Member] USD ($)	Sep. 30, 2014 Vessix Vascular, Inc. [Member] USD ($)	Sep. 30, 2010 Vessix Vascular, Inc. [Member] USD ($)	Sep. 30, 2014 Vessix Vascular, Inc. [Member] Clinical milestone [Member] USD ($)	Sep. 30, 2014 Vessix Vascular, Inc. [Member] Sales milestone [Member] USD ($)	Sep. 30, 2014 Vessix Vascular, Inc. [Member] Maximum [Member] USD ($)	Mar. 31, 2013 OctoPlus [Member] USD ($)	Mar. 31, 2012 OctoPlus [Member] USD ($)	Sep. 30, 2014 OctoPlus [Member] USD ($)	Oct. 31, 2012 OctoPlus [Member] EUR (€)	Sep. 30, 2012 OctoPlus [Member] USD ($)	Sep. 30, 2013 Nexeon MedSystems, Inc. [Member] USD ($)	Sep. 30, 2014 Nexeon MedSystems, Inc. [Member] USD ($)	Sep. 30, 2010 Nexeon MedSystems, Inc. [Member] USD ($)	Sep. 30, 2013 Nexeon MedSystems, Inc. [Member] Maximum [Member] USD ($)	Sep. 30, 2014 In Vitro Diagnostics [Member] USD ($)	Sep. 30, 2013 In Vitro Diagnostics [Member] USD ($)
Summary Of Significant Accounting Policies [Line Items]
Depreciation expense			$ 2,000,000	$ 2,100,000	$ 2,200,000
Company's ownership percentage												2.00%			20.00%				1.00%
Impairment loss on investment													1,200,000	1,200,000		100,000	5,300,000	4,700,000			2,500,000	2,400,000					800,000				1,000,000	6,500,000	4,100,000	100,000
Cost method of investment																	500,000
Gain on sale of investment	700,000	1,200,000	842,000	1,430,000	228,000															1,200,000
Milestone payment to be received																							700,000	700,000
Potential proceeds on achievement of future milestones																									3,300,000
Transfer to Investments			2,000
Gain on investments			1,500,000
Previous cost basis																												1,700,000
Investment in cost basis																														900,000
Offer price of shares issued and outstanding																													€ 0.52
Gain on sale of investments																										100,000
Carrying value of the investment			0	0
Revenue recognized from activity with companies in which it had strategic investment				100,000	100,000				100,000
Amortization expense			700,000	700,000	700,000
Goodwill			8,010,000	8,010,000																															8,000,000	8,000,000
Taxes collected from customers and remitted to governmental authorities			100,000	100,000	100,000
Product sales payment terms, general minimum			30 days
Product sales payment terms, general maximum			45 days
Deferred revenue			$ 300,000	$ 200,000
Major customer percentage of consolidated revenue						19.00%	19.00%	19.00%		10.00%	7.00%
Weighted average diluted shares outstanding excluded outstanding stock options			0.5	0.4	0.6